Skip to content
Riskpilot
← Back to search
Sign in
Get full access
SwePharm AB
AB
Active
Org 5565760930
Sandby 1641, 247 92
Södra Sandby
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 1999 · 26 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
SwePharm AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
2M
4M
6M
8M
4M
2020
7M
2021
3M
2022
0M
2023
0M
2024
EBITDA
SEK millions
3M
2M
1M
-0M
-1M
1M
2020
2M
+100%
2021
-1M
-150%
2022
0M
+100%
2023
0M
0%
2024
Income statement
SEK thousands
Item
2020
2021
2022
2023
2024
Revenue
3 532
7 010
2 588
361
51
Staff expenses
—
—
−213
−6
—
EBITDA
960
2 367
−704
−307
−182
Depreciation & amort.
−256
−269
−231
−147
−109
EBIT
704
2 098
−935
−454
−291
Net financials
510
−39
−40
27
−6
Profit before tax
739
1 678
398
32
32
Tax
−39
−348
−79
−0
−0
Net profit
700
1 330
319
32
32
Balance sheet
SEK thousands
Item
2020
2021
2022
2023
2024
Total assets
5 289
7 927
5 053
1 389
1 006
Equity
1 008
2 338
2 657
589
471
Long-term debt
1 531
1 722
0
—
0
Short-term debt
576
1 311
1 213
76
140
Total debt
2 107
3 033
1 213
76
140
Financial ratios
5-year trend
EBITDA margin
-356.9%
This company
15.8%
Market median
-2359% vs market
2020
2024
Equity ratio
46.8%
This company
38.2%
Market median
+23% vs market
2020
2024
Return on equity
6.8%
This company
18.4%
Market median
-63% vs market
2020
2024
Net profit margin
62.7%
This company
8.1%
Market median
+674% vs market
2020
2024
Asset turnover
0.05×
This company
1.12×
Market median
-96% vs market
2020
2024
Debt / equity
1.14×
This company
0.62×
Market median
-84% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on SwePharm AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
